Literature DB >> 3461777

Experience with acute subdural haematomas in New South Wales.

W A Stening, G Berry, N G Dan, B Kwok, J A Mandryk, I Ring, M Sewell, D A Simpson.   

Abstract

A retrospective survey of head injuries in NSW in 1977 and 1978 was conducted by the Trauma Subcommittee of the Neurosurgical Society of Australasia. Two hundred and ninety patients, who were found to have acute or subacute subdural haematomas, were considered. The mortality rate was 76%, with 19% making a satisfactory recovery. Several factors were found to produce significant improvement in outcome. The availability of neurosurgical facilities at the time of admission made a significant difference. Those patients who had decompressive operations also fared better. No patient survived without operation. Shock, defined as a systolic blood pressure lower than 90 mmHg for more than 60 min was associated with significantly increased mortality. The chance of developing a significant hypotensive episode was greater if two or more other parts of the body were injured. If three other areas were injured, the mortality was 100%. A case control study suggested that some 35 (16%) of all deaths could have resulted from preventable causes, notably delay in instituting definitive treatment and/or inadequate treatment of shock.

Entities:  

Mesh:

Year:  1986        PMID: 3461777     DOI: 10.1111/j.1445-2197.1986.tb07098.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  3 in total

1.  Predictors for functional recovery and mortality of surgically treated traumatic acute subdural hematomas in 256 patients.

Authors:  Kyu-Hong Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-03-31

2.  Outcome prediction in extradural haematomas.

Authors:  R J Cook; N W Dorsch; M R Fearnside; R Chaseling
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Damage control in the injured patient.

Authors:  Jeremy M Hsu; Tam N Pham
Journal:  Int J Crit Illn Inj Sci       Date:  2011-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.